Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZM008 |
| Synonyms | |
| Therapy Description |
ZM008 is an anti-LLT1 monoclonal antibody that impairs the interaction between LLT1 and CD161, potentially leading to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2023;11; Cancer Res (2024) 84 (6_Supplement): 7535). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZM008 | ZM-008|ZM 008 | ZM008 is an anti-LLT1 monoclonal antibody that impairs the interaction between LLT1 and CD161, potentially leading to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2023;11; Cancer Res (2024) 84 (6_Supplement): 7535). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |